Blue Oak taps AI specialist Exscientia for CNS drug discoveryUS startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK Share XBlue Oak taps AI specialist Exscientia for CNS drug discoveryhttps://pharmaphorum.com/news/blue-oak-taps-ai-specialist-exscientia-for-cns-drug-discovery/
Record number of health firms feature in UK top 100 private tech listA record number of health and medtech companies have been included in the Sunday Times Sage Tech Track Share XRecord number of health firms feature in UK top 100 private tech listhttps://pharmaphorum.com/news/babylon-among/
Could AI avert a future coronavirus pandemic?Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is Share XCould AI avert a future coronavirus pandemic?https://pharmaphorum.com/news/could-ai-avert-a-future-coronavirus-pandemic/
AI drug discovery firm Exscientia gets $60M cash injectionUK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round Share XAI drug discovery firm Exscientia gets $60M cash injectionhttps://pharmaphorum.com/news/ai-drug-discovery-firm-exscientia-gets-60m-cash-injection/
AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
AI specialist Exscientia forms rare disease JV with RallyBioUK artificial intelligence (AI) drug discovery company Exscientia has formed another R&D alliance, this time in the area Share XAI specialist Exscientia forms rare disease JV with RallyBiohttps://pharmaphorum.com/news/ai-specialist-exscientia-forms-rare-disease-jv-with-rallybio/
GSK adds to COPD pipeline as Exscientia deal bears fruitAI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D Share XGSK adds to COPD pipeline as Exscientia deal bears fruithttps://pharmaphorum.com/about-pharmaphorum/gsk-adds-to-copd-pipeline-as-exscientia-deal-bears-fruit/
AI drug R&D firm Exscientia expands into JapanAI drug R&D firm Exscientia has announced it has expanded into Japan, after clinching a major research deal Share XAI drug R&D firm Exscientia expands into Japanhttps://pharmaphorum.com/news/ai-drug-rd-firm-exscientia-expands-into-japan/
AI drug R&D company Exscientia signs deal with CelgeneUK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, Share XAI drug R&D company Exscientia signs deal with Celgenehttps://pharmaphorum.com/news/ai-drug-rd-company-exscientia-signs-deal-with-celgene/
